Cipla Medpro Of India Avoids S. Africa Firm’s Takeover Move
This article was originally published in PharmAsia News
Executive SummaryIndia's Cipla Medpro was saved from a takeover move by a South African drug maker when Cipla's major supplier, Cipla Limited, said it would cancel its agreement if the buyout occurred. Adcock Ingram, South Africa's second-largest pharmaceutical company, had planned to buy Cipla Medpro to increase its share of the generics market. Cipla Limited, rejected the offer, however, causing Adcock to cancel its proposed takeover. The South African firm called for the Johannesburg Stock Exchange to launch an investigation into Cipla Limited's agreements with Cipla Medpro. (Click here for more
You may also be interested in...
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.